[HTML][HTML] Ewing sarcoma—diagnosis, treatment, clinical challenges and future perspectives
SK Zöllner, JF Amatruda, S Bauer, S Collaud… - Journal of clinical …, 2021 - mdpi.com
Ewing sarcoma, a highly aggressive bone and soft-tissue cancer, is considered a prime
example of the paradigms of a translocation-positive sarcoma: a genetically rather simple …
example of the paradigms of a translocation-positive sarcoma: a genetically rather simple …
[HTML][HTML] Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies
I Lilienthal, N Herold - International journal of molecular sciences, 2020 - mdpi.com
Osteosarcoma is the most common primary malignant bone tumour in children and
adolescents. Due to micrometastatic spread, radical surgery alone rarely results in cure …
adolescents. Due to micrometastatic spread, radical surgery alone rarely results in cure …
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised …
YP Chen, X Liu, Q Zhou, KY Yang, F Jin, XD Zhu, M Shi… - The Lancet, 2021 - thelancet.com
Background Patients with locoregionally advanced nasopharyngeal carcinoma have a high
risk of disease relapse, despite a high proportion of patients attaining complete clinical …
risk of disease relapse, despite a high proportion of patients attaining complete clinical …
Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium
PURPOSE Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood.
Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent …
Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent …
[HTML][HTML] Future directions in the treatment of osteosarcoma
A Smrke, PM Anderson, A Gulia, S Gennatas… - Cells, 2021 - mdpi.com
Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd–
3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate …
3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate …
[HTML][HTML] Current and future treatment strategies for rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, and can be
subcategorized histologically and/or based on PAX-FOXO1 fusion gene status. Over the last …
subcategorized histologically and/or based on PAX-FOXO1 fusion gene status. Over the last …
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a …
P Pautier, A Italiano, S Piperno-Neumann… - The Lancet …, 2022 - thelancet.com
Background Metastatic leiomyosarcomas have a poor prognosis, and currently doxorubicin
alone is used as the standard first-line treatment. Doxorubicin combined with trabectedin …
alone is used as the standard first-line treatment. Doxorubicin combined with trabectedin …
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials
JH Haduong, CM Heske… - Pediatric blood & …, 2022 - Wiley Online Library
Children and adolescents with rhabdomyosarcoma (RMS) comprise a heterogeneous
population with variable overall survival rates ranging between approximately 6% and 100 …
population with variable overall survival rates ranging between approximately 6% and 100 …
Recent progress in the treatment of cancer in children
E Butler, K Ludwig, HL Pacenta… - CA: a cancer journal …, 2021 - Wiley Online Library
Although significant improvements have been made in the outcomes of children with cancer,
the pace of improvement has slowed in recent years as the limits of therapy intensification …
the pace of improvement has slowed in recent years as the limits of therapy intensification …
Randomized phase II trial of vincristine-irinotecan with or without temozolomide, in children and adults with relapsed or refractory rhabdomyosarcoma: A European …
AS Defachelles, E Bogart, M Casanova… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE The VIT-0910 trial was conducted to evaluate efficacy and safety of the
vincristine-irinotecan combination with and without temozolomide (VIT and VI, respectively) …
vincristine-irinotecan combination with and without temozolomide (VIT and VI, respectively) …